Hepion Pharmaceuticals (HEPA)
NASDAQ:HEPA
Holding HEPA?
Track your performance easily

Hepion Pharmaceuticals (HEPA) Income Statement

702 Followers

Hepion Pharmaceuticals Income Statement

Last quarter (Q ), Hepion Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Hepion Pharmaceuticals's net income was $-3.93M. See Hepion Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 31.57M$ 45.26M$ 43.62M$ 30.40M$ 20.15M$ 7.77M
Operating Income
$ -34.76M$ -48.45M$ -45.49M$ -30.40M$ -20.15M$ -7.77M
Net Non Operating Interest Income Expense
$ 40.40K$ -9.46K$ -10.16K$ -8.86K$ -31.23K$ -555.00K
Other Income Expense
$ -5.19M$ -4.07M$ -1.46M-$ 6.05K$ 160.00K
Pretax Income
$ -31.74M$ -49.34M$ -45.08M$ -32.70M$ -20.30M$ -8.33M
Tax Provision
$ -3.41M$ -409.02K$ -2.88M-$ 30.58K$ -908.68K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -28.37M$ -48.93M$ -45.34M$ -32.72M$ -20.36M$ -12.86M
Basic EPS
$ -6.40$ -12.32$ -11.80$ -9.40$ -42.00$ -119.00
Diluted EPS
$ -6.40$ -12.32$ -11.80$ -9.40$ -42.00$ -119.00
Basic Average Shares
$ 19.12M$ 3.97M$ 3.81M$ 3.51M$ 483.89K$ 102.16K
Diluted Average Shares
$ 19.12M$ 3.97M$ 3.81M$ 3.51M-$ 102.16K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 34.76M$ 45.26M$ 43.62M$ 30.40M$ 20.15M$ 7.77M
Net Income From Continuing And Discontinued Operation
$ -28.37M$ -48.93M$ -42.20M$ -32.72M$ -20.35M$ -7.42M
Normalized Income
$ -17.97M$ -43.31M-$ -25.83M--
Interest Expense
------
EBIT
$ -31.06M$ -49.33M$ -45.07M$ -32.71M$ -20.27M$ -7.77M
EBITDA
$ -31.00M$ -49.26M$ -45.00M$ -32.63M$ -20.23M$ -7.26M
Currency in USD

Hepion Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis